FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162501548> ?p ?o ?g. }

• W2162501548 abstract "Expression of indoleamine 2,3-dioxygenase (IDO) in primary breast cancer increases tumor growth and metastasis. However, the clinical significance of stromal IDO and the regulation of stromal IDO are unclear.Metabolomics and enzyme-linked immunosorbent assay (ELISA) were used to study the effect of cyclooxygenase-2 (COX-2)-overexpressing breast cancer cells on IDO expression in co-cultured human breast fibroblasts. Biochemical inhibitors and short-hairpin RNA (shRNA) were used to clarify how prostaglandin E2 (PGE2) upregulates IDO expression. Associations of stromal IDO with clinicopathologic parameters were tested in tumor specimens. An orthotopic animal model was used to examine the effect of COX-2 and IDO inhibitors on tumor growth.Kynurenine, the metabolite generated by IDO, increases in the supernatant of fibroblasts co-cultured with COX-2-overexpressing breast cancer cells. PGE2 released by cancer cells upregulates IDO expression in fibroblasts through an EP4/signal transducer and activator of transcription 3 (STAT3)-dependent pathway. Conversely, fibroblast-secreted kynurenine promotes the formation of the E-cadherin/Aryl hydrocarbon receptor (AhR)/S-phase kinase-associated protein 2 (Skp2) complex, resulting in degradation of E-cadherin to increase breast cancer invasiveness. The enhancement of motility of breast cancer cells induced by co-culture with fibroblasts is suppressed by the IDO inhibitor 1-methyl-tryptophan. Pathological analysis demonstrates that upregulation of stromal IDO is a poor prognosis factor and is associated with of COX-2 overexpression. Co-expression of cancer COX-2 and stromal IDO predicts a worse disease-free and metastasis-free survival. Finally, COX-2 and IDO inhibitors inhibit tumor growth in vivo.Integration of metabolomics and molecular and pathological approaches reveals the interplay between cancer and stroma via COX-2, and IDO promotes tumor progression and predicts poor patient survival." @default.
• W2162501548 created "2016-06-24" @default.
• W2162501548 creator A5006129657 @default.
• W2162501548 creator A5037240103 @default.
• W2162501548 creator A5068751664 @default.
• W2162501548 creator A5070326975 @default.
• W2162501548 creator A5083933121 @default.
• W2162501548 creator A5089538326 @default.
• W2162501548 date "2014-07-25" @default.
• W2162501548 modified "2023-10-12" @default.
• W2162501548 title "Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression" @default.
• W2162501548 cites W1956469105 @default.
• W2162501548 cites W1967857971 @default.
• W2162501548 cites W1968291309 @default.
• W2162501548 cites W1969474715 @default.
• W2162501548 cites W1970050679 @default.
• W2162501548 cites W1975826537 @default.
• W2162501548 cites W1978225946 @default.
• W2162501548 cites W1986321253 @default.
• W2162501548 cites W1995675594 @default.
• W2162501548 cites W1998142996 @default.
• W2162501548 cites W2013958910 @default.
• W2162501548 cites W2014837971 @default.
• W2162501548 cites W2024425168 @default.
• W2162501548 cites W2036680234 @default.
• W2162501548 cites W2044182846 @default.
• W2162501548 cites W2044706920 @default.
• W2162501548 cites W2049820772 @default.
• W2162501548 cites W2053385401 @default.
• W2162501548 cites W2058118671 @default.
• W2162501548 cites W2059327215 @default.
• W2162501548 cites W2070732038 @default.
• W2162501548 cites W2078972833 @default.
• W2162501548 cites W2083006984 @default.
• W2162501548 cites W2085852125 @default.
• W2162501548 cites W2090410108 @default.
• W2162501548 cites W2093342110 @default.
• W2162501548 cites W2097156202 @default.
• W2162501548 cites W2101037339 @default.
• W2162501548 cites W2115424486 @default.
• W2162501548 cites W2128058116 @default.
• W2162501548 cites W2131860315 @default.
• W2162501548 cites W2144030304 @default.
• W2162501548 cites W2146914242 @default.
• W2162501548 cites W2159731673 @default.
• W2162501548 cites W2162647235 @default.
• W2162501548 cites W2169281418 @default.
• W2162501548 doi "https://doi.org/10.1186/s13058-014-0410-1" @default.
• W2162501548 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4220086" @default.
• W2162501548 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25060643" @default.
• W2162501548 hasPublicationYear "2014" @default.
• W2162501548 type Work @default.
• W2162501548 sameAs 2162501548 @default.
• W2162501548 citedByCount "112" @default.
• W2162501548 countsByYear W21625015482014 @default.
• W2162501548 countsByYear W21625015482015 @default.
• W2162501548 countsByYear W21625015482016 @default.
• W2162501548 countsByYear W21625015482017 @default.
• W2162501548 countsByYear W21625015482018 @default.
• W2162501548 countsByYear W21625015482019 @default.
• W2162501548 countsByYear W21625015482020 @default.
• W2162501548 countsByYear W21625015482021 @default.
• W2162501548 countsByYear W21625015482022 @default.
• W2162501548 countsByYear W21625015482023 @default.
• W2162501548 crossrefType "journal-article" @default.
• W2162501548 hasAuthorship W2162501548A5006129657 @default.
• W2162501548 hasAuthorship W2162501548A5037240103 @default.
• W2162501548 hasAuthorship W2162501548A5068751664 @default.
• W2162501548 hasAuthorship W2162501548A5070326975 @default.
• W2162501548 hasAuthorship W2162501548A5083933121 @default.
• W2162501548 hasAuthorship W2162501548A5089538326 @default.
• W2162501548 hasBestOaLocation W21625015481 @default.
• W2162501548 hasConcept C104317684 @default.
• W2162501548 hasConcept C121608353 @default.
• W2162501548 hasConcept C126322002 @default.
• W2162501548 hasConcept C16930146 @default.
• W2162501548 hasConcept C171958077 @default.
• W2162501548 hasConcept C2776706248 @default.
• W2162501548 hasConcept C2778923194 @default.
• W2162501548 hasConcept C2779013556 @default.
• W2162501548 hasConcept C33594762 @default.
• W2162501548 hasConcept C502942594 @default.
• W2162501548 hasConcept C515207424 @default.
• W2162501548 hasConcept C530470458 @default.
• W2162501548 hasConcept C55493867 @default.
• W2162501548 hasConcept C555283112 @default.
• W2162501548 hasConcept C62478195 @default.
• W2162501548 hasConcept C71924100 @default.
• W2162501548 hasConcept C83478079 @default.
• W2162501548 hasConcept C86339819 @default.
• W2162501548 hasConcept C86803240 @default.
• W2162501548 hasConcept C95444343 @default.
• W2162501548 hasConcept C96232424 @default.
• W2162501548 hasConceptScore W2162501548C104317684 @default.
• W2162501548 hasConceptScore W2162501548C121608353 @default.
• W2162501548 hasConceptScore W2162501548C126322002 @default.
• W2162501548 hasConceptScore W2162501548C16930146 @default.
• W2162501548 hasConceptScore W2162501548C171958077 @default.
• W2162501548 hasConceptScore W2162501548C2776706248 @default.
• W2162501548 hasConceptScore W2162501548C2778923194 @default.

• next